BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34237612)

  • 21. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of microsatellite instability in sporadic colon cancers.
    Sinicrope FA; Sargent DJ
    Curr Opin Oncol; 2009 Jul; 21(4):369-73. PubMed ID: 19444104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.
    Dienstmann R; Salazar R; Tabernero J
    J Clin Oncol; 2015 Jun; 33(16):1787-96. PubMed ID: 25918287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.
    Taieb J; André T; Auclin E
    Cancer Treat Rev; 2019 May; 75():1-11. PubMed ID: 30849607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
    Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
    Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer.
    Baek DW; Kang BW; Lee SJ; Kim HJ; Park SY; Park JS; Choi GS; Baek JH; Kim JG
    In Vivo; 2019; 33(2):649-657. PubMed ID: 30804154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
    Yang L; Sun Y; Huang XE; Yu DS; Zhou JN; Zhou X; Li DZ; Guan X
    Asian Pac J Cancer Prev; 2015; 16(4):1545-51. PubMed ID: 25743829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
    Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
    Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
    Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
    Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
    Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
    Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post-metastatic liver biochip modeling.
    Bayir Garbioglu D; Demir N; Ozel C; Avci H; Dincer M
    FASEB J; 2021 Sep; 35(9):e21834. PubMed ID: 34403553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of molecular biomarkers to inform adjuvant therapy for colon cancer.
    Mettu NB; Hurwitz H; Hsu DS
    Oncology (Williston Park); 2013 Aug; 27(8):746-54. PubMed ID: 24133820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant therapy for colon cancer.
    Aranha O; Benson AB
    Curr Gastroenterol Rep; 2007 Oct; 9(5):415-21. PubMed ID: 17991344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.